Wed, April 5, 2023
Tue, April 4, 2023
Mon, April 3, 2023
Sat, April 1, 2023
Fri, March 31, 2023
Thu, March 30, 2023

Brian Cheng Maintained (BCAB) at Buy with Decreased Target to $19 on, Apr 3rd, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-19-on-apr-3rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Brian Cheng of JP Morgan, Maintained "BioAtla, Inc." (BCAB) at Buy with Decreased Target from $23 to $19 on, Apr 3rd, 2023.

Brian has made no other calls on BCAB in the last 4 months.



There are 5 other peers that have a rating on BCAB. Out of the 5 peers that are also analyzing BCAB, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Tiago Fauth of "Credit Suisse" Reiterated at Hold and Held Target at $8 on, Friday, March 24th, 2023


These are the ratings of the 4 analyists that currently disagree with Brian


  • Thomas Shrader of "BTIG" Maintained at Strong Buy with Decreased Target to $13 on, Tuesday, March 28th, 2023
  • Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $12 on, Monday, March 27th, 2023
  • Arthur He of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $17 on, Friday, March 24th, 2023
  • Tony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $25 on, Friday, March 24th, 2023

Publication Contributing Sources